Maryam Akbari1, Vahidreza Ostadmohammadi2, Reza Tabrizi1, Kamran B Lankarani3, Seyed Taghi Heydari3, Elaheh Amirani2, Russel J Reiter4, Zatollah Asemi5. 1. Health Policy Research Center, Institute of Health, Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran. 2. Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Islamic Republic of Iran. 3. Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran. 4. Department of Cellular and Structural Biology, University of Texas Health Science, Center, San Antonio, TX, USA. 5. Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Islamic Republic of Iran. asemi_r@yahoo.com.
Abstract
OBJECTIVE: This systematic review and meta-analysis of randomized controlled trials (RCTs) was carried out to determine the effect of melatonin supplementation on the inflammatory markers among individuals with metabolic syndrome (MetS) and related disorders. METHODS: We searched the following databases up to March 2018: PubMed, MEDLINE, EMBASE, Web of Science, and Cochrane Central Register of Controlled Trials. Three reviewers independently assessed study eligibility, extracted data, and evaluated risk of bias of included primary studies. Statistical heterogeneity was assessed using Cochran's Q test and I-square (I2) statistic. Data were pooled using the random effect model and standardized mean difference (SMD) was considered as the summary effect size. RESULTS: Six trials of 317 potential reports were identified to be suitable for our meta-analysis. The pooled results using random effects model indicated that melatonin supplementation significantly reduced C-reactive protein (CRP) (SMD = - 1.80; 95% CI - 3.27, - 0.32; P = 0.01; I2: 95.2) and interleukin 6 (IL-6) concentrations (SMD = - 2.02; 95% CI - 3.57, - 0.47; P = 0.01; I2: 91.2) among patients with MetS and related disorders; however, it did not affect tumor necrosis factor-α (TNF-α) concentrations (SMD = - 1.87; 95% CI - 3.81, 0.07; P = 0.05; I2: 94.4). CONCLUSIONS: In summary, the current meta-analysis showed the promising effect of melatonin administration on reducing CRP and IL-6, but not TNF-α levels among patients with MetS and related disorders. Additional prospective studies are recommended using higher supplementation doses and longer intervention period.
OBJECTIVE: This systematic review and meta-analysis of randomized controlled trials (RCTs) was carried out to determine the effect of melatonin supplementation on the inflammatory markers among individuals with metabolic syndrome (MetS) and related disorders. METHODS: We searched the following databases up to March 2018: PubMed, MEDLINE, EMBASE, Web of Science, and Cochrane Central Register of Controlled Trials. Three reviewers independently assessed study eligibility, extracted data, and evaluated risk of bias of included primary studies. Statistical heterogeneity was assessed using Cochran's Q test and I-square (I2) statistic. Data were pooled using the random effect model and standardized mean difference (SMD) was considered as the summary effect size. RESULTS: Six trials of 317 potential reports were identified to be suitable for our meta-analysis. The pooled results using random effects model indicated that melatonin supplementation significantly reduced C-reactive protein (CRP) (SMD = - 1.80; 95% CI - 3.27, - 0.32; P = 0.01; I2: 95.2) and interleukin 6 (IL-6) concentrations (SMD = - 2.02; 95% CI - 3.57, - 0.47; P = 0.01; I2: 91.2) among patients with MetS and related disorders; however, it did not affect tumor necrosis factor-α (TNF-α) concentrations (SMD = - 1.87; 95% CI - 3.81, 0.07; P = 0.05; I2: 94.4). CONCLUSIONS: In summary, the current meta-analysis showed the promising effect of melatonin administration on reducing CRP and IL-6, but not TNF-α levels among patients with MetS and related disorders. Additional prospective studies are recommended using higher supplementation doses and longer intervention period.
Authors: Peter Willeit; Simon G Thompson; Stefan Agewall; Göran Bergström; Horst Bickel; Alberico L Catapano; Kuo-Liong Chien; Eric de Groot; Jean-Philippe Empana; Thorleif Etgen; Oscar H Franco; Bernhard Iglseder; Stein H Johnsen; Maryam Kavousi; Lars Lind; Jing Liu; Ellisiv B Mathiesen; Giuseppe D Norata; Michael H Olsen; Aikaterini Papagianni; Holger Poppert; Jackie F Price; Ralph L Sacco; David N Yanez; Dong Zhao; Ulf Schminke; Alpaslan Bülbül; Joseph F Polak; Matthias Sitzer; Albert Hofman; Liliana Grigore; Marcus Dörr; Ta-Chen Su; Pierre Ducimetière; Wuxiang Xie; Kimmo Ronkainen; Stefan Kiechl; Tatjana Rundek; Christine Robertson; Björn Fagerberg; Lena Bokemark; Helmuth Steinmetz; M Arfan Ikram; Henry Völzke; Hung-Ju Lin; Matthieu Plichart; Tomi-Pekka Tuomainen; Moise Desvarieux; Stela McLachlan; Caroline Schmidt; Jussi Kauhanen; Johann Willeit; Matthias W Lorenz; Dirk Sander Journal: Eur J Prev Cardiol Date: 2014-11-21 Impact factor: 7.804
Authors: Andrew O Odegaard; David R Jacobs; Otto A Sanchez; David C Goff; Alexander P Reiner; Myron D Gross Journal: Cardiovasc Diabetol Date: 2016-03-24 Impact factor: 8.949
Authors: Alejandro Romero; Eva Ramos; Francisco López-Muñoz; Cristóbal De Los Ríos; Javier Egea; Emilio Gil-Martín; René Pita; Juan J Torrado; Dolores R Serrano; Antonio Juberias Journal: Diseases Date: 2021-04-10
Authors: Diana Maria Chitimus; Mihaela Roxana Popescu; Suzana Elena Voiculescu; Anca Maria Panaitescu; Bogdan Pavel; Leon Zagrean; Ana-Maria Zagrean Journal: Biomolecules Date: 2020-08-20